Biomemory’s DNA Shield stores critical data in synthetic DNA, out of reach of cyberattacks
- Biomemory has introduced DNA Shield, designed to provide secure, offline, airless storage of critical digital assets in synthetic DNA.
- The company foresees challenges to the resilience of those assets (also known as “cold data”) and has hinted at the introduction of what it calls Molecular IT.
- Biomemory is co-chair of the DNA Data Storage Alliance
Commercial DNA data storage company Biomemory has introduced DNA Shield, a purpose-built synthetic DNA repository service that ensures critical digital assets remain untouched by cybercriminals and emerging technologies such as artificial intelligence.
The so-called cold data represents 60% of all data in the world and refers to information that cannot be altered. They can be passwords and biometric data or incontrovertible data, facts, financials and other material that serves as a record.
DNA Shield stores data in DNA using a designed coding scheme that ensures its biosafety: it is a physical molecule that stores information long-term without energy. Pilot spaces have been opened, ahead of full service expected in 2027.
Latest videos ofTechnologyRadar
A DNA shield
Biomemory launched DNA Shield following its acquisition of Boston-based DNA storage pioneer Catalog Technologies in March 2026, and aims to provide organizations with DNA data storage.
The data can be biometrics, cryptographic keys or accounts. It could even be intellectual property, plans, unique or proprietary know-how. Encrypting data in synthetic DNA and storing it in a medium one million times denser than magnetic, offline, air-gapped storage is arguably the most secure storage available, potentially with a lifespan of 150 years.
“DNA Shield is the moment when Biomemory moves from demonstrating science to offering a commercial product,” says Laurent Guengant, CEO of Biomemory. “Organizations need a way to preserve their most critical digital assets, cryptographic keys, core intellectual property, regulated records and institutional memory for the long term, somewhere no provider, cloud or system can reach, and prove that it still works over time.”
The molecular computing platform
Availability of the DNA Shield service is currently limited to a few pilots, from October 15, 2026 to mid-2027. Biomemory tells us that a full service will be rolled out after that point, and its launch makes it the first company to launch a molecular IT product.
Vincent Franceschini, vice president of product management at Biomemory and co-president of the DNA Data Storage Alliance, said, “DNA Shield is based on the same molecular platform we’ve spent years industrializing, but this is the first time we’ve asked a customer to rely on it operationally rather than as a research demonstration. Getting it right, from start to finish, from encoding to authoritative retrieval, is what makes us the first company to bring molecular IT to market.”
Organizations interested in DNA Shield will pay a subscription starting at €10,000 per month, and early access requests are open directly through Biomemory.
Follow TechRadar on Google News and add us as a preferred source to receive news, reviews and opinions from our experts in your feeds.
Post Comment